Evaluating MicroRNA's as Prognostic Determinants in Stage II Colon Cancer

Early stage colon cancer treated with surgery alone has a small, but real, risk for recurrence elsewhere in the body. Treatment with chemotherapy greatly reduces this risk for a small proportion of patients, but carries other health risks associated with drug treatment. Patients with early stage colon cancer must choose between these alternatives. A test that can determine which early colon cancers have an aggressive tendency (very likely to recur and spread) and those that are unlikely to recur would greatly benefit patients and their oncologists. A recently discovered type of bio-molecule known as microRNA shows promise in distinguishing aggressive from non-aggressive early colon cancers. This work is aimed at developing a predictive test based on microRNA profiles of colon tumors.

Organization: 
Maine Center for Cancer Medicine
Researcher: 
Matthew Dugan
Grant Amount Given: 
$78,000
Year Issued: 
2010
Period: 
Annual
Grant Category: 
Research
Types of Cancer: 
Colon
Grant Duration: 
1 Year Pilot Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2010 Evaluating MicroRNA's as Prognostic Determinants in Stage II Colon Cancer $78,000 Research Maine Center for Cancer Medicine
2008 Colorectal Cancer Screenings $6,839 Screening Maine Center for Cancer Medicine
2007 Toolkit for Colorectal Cancer $4,800 Education Maine Center for Cancer Medicine
2006 Molecular Predictors of Iressa Response in Lung Cancer Patients $68,241 Research Maine Center for Cancer Medicine
2006 Cancer Risk and Prevention $1,862 Education Maine Center for Cancer Medicine
2004 Molecular Markers of Prognosis and Response to Therapy in Breast Cancer $70,500 Research Maine Center for Cancer Medicine
2003 Molecular Indicators of Prognosis and Response to Therapy in Breast Cancer $60,700 Research Maine Center for Cancer Medicine
2001 Cancer Genetics Research $87,000 Research Maine Center for Cancer Medicine